Fourteen Women Urge Action After Mail-Order Abortion Drugs Leave Them Vulnerable

Fourteen women who suffered severe complications from abortion drugs sent Acting Attorney General Todd Blanche a letter on July 8, demanding he settle a federal lawsuit and restore safety safeguards. The letter exposes a consumer protection crisis that unfolded when the FDA removed in-person dispensing requirements for mifepristone, allowing pharmaceutical companies to ship high-risk drugs across state lines without medical oversight.

The FDA's 2023 decision to eliminate Risk Evaluation and Mitigation Strategy safeguards drew criticism from women who say the lax rules left them vulnerable to medical harm and coercion. An April 2025 Ethics and Public Policy Center study analyzed 865,727 mifepristone prescriptions and found a 10.93 percent rate of serious adverse events including sepsis, infection, and hemorrhaging within 45 days. The figure stands in stark contrast to the FDA's official warning of less than 0.5 percent risk.

"Contrary to what some may claim, the abortion pill is not like Tylenol," stated EPPC President Ryan T. Anderson and Director of Data Analysis Jamie Bryan Hall. "We find that one out of every ten women who takes the abortion pill will suffer from a serious adverse event, like hemorrhage or infection, soon afterward."

The deregulation also transformed mifepristone into a tool for abusers who bypass medical screening entirely. Rosalie Markezich, a plaintiff in Louisiana v. FDA, discovered her then-boyfriend ordered the drugs online without her consent after she refused to terminate her pregnancy. "If mail-order abortion wasn't a thing, I'm 100 percent sure I would have my child," Markezich stated. "I do not believe a doctor would have prescribed me the drugs if I told her I did not want them."

The mail-order model enables criminal coercion without medical intervention. Army Captain Brandon Jones-Adams received a 12-year prison sentence in June 2026 for secretly giving mifepristone to a junior soldier. Prosecutors confirmed he used a fake name to order the drugs online.

Judicial pushback against the FDA's deregulation accelerated in May 2026 when the 5th Circuit Court of Appeals unanimously granted Louisiana's request to stay the 2023 REMS modification. Judge Kyle Duncan determined the agency's relaxation of guardrails "likely lacked a basis in data and scientific literature." The ruling noted Louisiana pays significant Medicaid costs for emergency care when women suffer complications from mailed mifepristone.

Pharmaceutical companies Danco Laboratories and GenBioPro intervened in the lawsuit to protect their market share as mifepristone accounts for more than 70 percent of U.S. abortions. The FDA continued relaxing requirements despite receiving 36 death reports associated with the drug since 2000 and mounting adverse event data contradicting its safety assurances.

Planned Parenthood CEO Alexis McGill Johnson maintains "Mifepristone is safe and effective," citing more than 7.5 million users over 25 years. Hemorrhage survivor Haile McAnally counters that narrative from personal experience. "I fell prey to the propaganda surrounding the abortion pill — and it nearly took my life," McAnally stated. "Now these drugs are being shipped across the country with little to no oversight."

Nurse Jessica Williams, who survived coercion from her estranged husband, emphasizes the need for proper medical protocols. "Every woman deserves to make decisions free from coercion or pressure and with appropriate medical support, screenings and safeguards," Williams said.

Blanche faces immediate pressure as his Senate Judiciary Committee confirmation hearings approach on July 15-16. The 5th Circuit has scheduled an expedited hearing for September 2026 in Louisiana v. FDA, creating a narrow window for the Justice Department to intervene.

The human toll carries a price tag for taxpayers as well. Louisiana identified $92,000 in Medicaid costs paid in 2025 for emergency care for just two women who needed treatment after taking mifepristone received by mail. The state projects hundreds of thousands in ongoing expenses as approximately 1,000 mifepristone-induced abortions occur monthly under the current deregulated system.

Restoring the FDA's original 2000 REMS requirements would mandate in-person dispensing and medical oversight, preventing abusers from ordering drugs secretly and ensuring patients receive proper screening for conditions like ectopic pregnancy. Enforcement of the 1873 Comstock Act, which prohibits mailing abortion medications, would provide additional consumer protections against corporate negligence.

The 14 women who signed the letter present Blanche with a choice between protecting women from harm or maintaining a system that prioritizes pharmaceutical profits over patient safety. Their stories carry a message that extends beyond courtroom filings and political hearings. These are women who bled, suffered, and nearly died — and who now stand asking the government to keep it from happening to someone else.